Correlation Engine 2.0
Clear Search sequence regions


  • abc transporters (1)
  • amides (2)
  • ATP (2)
  • BCRP (3)
  • behaviour (1)
  • cases (1)
  • doxorubicin (1)
  • elacridar (3)
  • MRP1 (2)
  • neoplasm proteins (2)
  • P gp (9)
  • tariquidar (3)
  • tetrazoles (3)
  • Sizes of these terms reflect their relevance to your search.

    New 2,5- and 1,5-disubstituted tetrazoles, and 2,5-disubstituted-1,3,4-oxadiazoles were synthesized as tariquidar and elacridar derivatives and studied as multidrug resistance (MDR) reversers. Their behaviour on the three ABC transporters P-gp, MRP1 and BCRP was investigated. All compounds inhibited the P-gp transport activity in MDCK-MDR1 cells overexpressing P-gp, showing EC50 values even in the low nanomolar range (compounds 15, 22). Oxadiazole derivatives were able to increase the antiproliferative effect of doxorubicin in MDCK-MDR1 and in HT29/DX cells confirming their nature of P-gp modulators, with derivative 15 being the most potent in these assays. Compound 15 also displayed a dual inhibitory effect showing good activities towards both P-gp and BCRP. A computational study suggested a common interaction pattern on P-gp for most of the potent compounds. The bioisosteric substitution of the amide group of lead compounds allowed identifying a new set of potent oxadiazole derivatives that modulate MDR through inhibition of the P-gp efflux activity. If compared to previous amide derivatives, the introduction of the heterocycle rings greatly enhances the activity on P-gp, introduces in two compounds a moderate inhibitory activity on MRP1 and maintains in some cases the effect on BCRP, leading to the unveiling of dual inhibitor 15. Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

    Citation

    Laura Braconi, Silvia Dei, Marialessandra Contino, Chiara Riganti, Gianluca Bartolucci, Dina Manetti, Maria Novella Romanelli, Maria Grazia Perrone, Nicola Antonio Colabufo, Stefano Guglielmo, Elisabetta Teodori. Tetrazole and oxadiazole derivatives as bioisosteres of tariquidar and elacridar: New potent P-gp modulators acting as MDR reversers. European journal of medicinal chemistry. 2023 Nov 05;259:115716

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 37573829

    View Full Text